We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

By LabMedica International staff writers
Posted on 22 Oct 2024
Print article
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated number of hip and knee arthroplasties is expected to quadruple within the next 10 to 20 years. PJI impacts over 2% of these patients and has become the leading cause of revision arthroplasty. Rapid and accurate diagnosis of PJI is crucial for ensuring that patients receive the most suitable surgical or antimicrobial treatment plan. Now, a state-of-the-art, high-accuracy point-of-care test is being developed to diagnose PJI in under five minutes.

InfectoTest GmbH (Berlin, Germany) is developing InfectoSynovia, a rapid and high-accuracy test designed to identify PJI in less than five minutes. This test employs an innovative electrochemical analysis technique that requires only a minimal sample of synovial fluid. InfectoSynovia aims to significantly decrease the diagnosis time to under five minutes while providing excellent sensitivity and specificity, using a sample as small as 50 microliters (µl) of synovial fluid.

With InfectoTest's unique electrochemical analysis approach, complemented by software that aids in the precise interpretation of results, InfectoSynovia will be capable of detecting low-grade and culture-negative infections. This groundbreaking technology aims to transform the diagnosis of PJI, addressing an escalating global demand as the prevalence of joint replacements increases with aging populations.

"Our InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection,” said Svetlana Karbysheva, MD, PhD., Managing Director of InfectoTest.

Related Links:
InfectoTest GmbH

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Sekisui Diagnostics UK Ltd.